|
1
|
Plataniotis G and Castiglione M; ESMO
Guidelines Working Group, : Endometrial cancer: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 21 (Suppl 5):v41–v45. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Setiawan VW, Yang HP, Pike MC, McCann SE,
Yu H, Xiang YB, Wolk A, Wentzensen N, Weiss NS, Webb PM, et al:
Type I and II endometrial cancers: Have they different risk
factors? J Clin Oncol. 31:2607–2618. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Braun MM, Overbeek-Wager EA and Grumbo RJ:
Diagnosis and management of endometrial cancer. Am Fam Physician.
93:468–474. 2016.PubMed/NCBI
|
|
5
|
Kyo S and Nakayama K: Endometrial cancer
as a metabolic disease with dysregulated PI3K signaling: Shedding
light on novel therapeutic strategies. Int J Mol Sci. 21:60732020.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lauby-Secretan B, Scoccianti C, Loomis D,
Grosse Y, Bianchini F and Straif K; International Agency for
Research on Cancer Handbook Working Group, : Body fatness and
cancer-viewpoint of the IARC Working Group. N Engl J Med.
375:794–798. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Frezza C: Mitochondrial metabolites:
Undercover signalling molecules. Interface Focus. 7:201601002017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Akram M: Citric acid cycle and role of its
intermediates in metabolism. Cell Biochem Biophys. 68:475–478.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Raimundo N, Baysal BE and Shadel GS:
Revisiting the TCA cycle: Signaling to tumor formation. Trends Mol
Med. 17:641–649. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Picaud S, Kavanagh KL, Yue WW, Lee WH,
Muller-Knapp S, Gileadi O, Sacchettini J and Oppermann U:
Structural basis of fumarate hydratase deficiency. J Inherit Metab
Dis. 34:671–676. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tomlinson IPM, Alam NA, Rowan AJ, Barclay
E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, et
al: Germline mutations in FH predispose to dominantly inherited
uterine fibroids, skin leiomyomata and papillary renal cell cancer.
Nat Genet. 30:406–610. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu C, Dillon J, Beavis AL, Liu Y,
Lombardo K, Fader AN, Hung CF, Wu TC, Vang R, Garcia JE and Xing D:
Prevalence of somatic and germline mutations of fumarate hydratase
in uterine leiomyomas from young patients. Histopathology.
76:354–365. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yuan SSF, Hou MF, Hsieh YC, Huang CY, Lee
YC, Chen YJ and Lo S: Role of MRE11 in cell proliferation, tumor
invasion, and DNA repair in breast cancer. J Natl Cancer Inst.
104:1485–1502. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yeung KT and Yang J:
Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol.
11:28–39. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sciacovelli M, Gonçalves E, Johnson TI,
Zecchini VR, da Costa AS, Gaude E, Drubbel AV, Theobald SJ, Abbo
SR, Tran MG, et al: Fumarate is an epigenetic modifier that elicits
epithelial-to-mesenchymal transition. Nature. 537:544–547. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Michalova K, Tretiakova M, Pivovarcikova
K, Alaghehbandan R, Perez Montiel D, Ulamec M, Osunkoya A, Trpkov
K, Yuan G, Grossmann P, et al: Expanding the morphologic spectrum
of chromophobe renal cell carcinoma: A study of 8 cases with
papillary architecture. Ann Diagn Pathol. 44:1514482020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen T, Peng Y, Lei T, Wu C, Wang H and
Shi Y: Low-grade oncocytic tumour (LOT) of the kidney is
characterised by GATA3 positivity, FOXI1 negativity and mTOR
pathway mutations. Pathol Oncol Res. 29:16108522023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang W, Chu J, Zou YW, Jiang YX, Wei ZM,
Zhong DC, Liu Y, Li YJ and Yu WJ: Clinicopathological
characteristics of fumarate hydratase-deficient renal cell
carcinoma. Zhonghua Bing Li Xue Za Zhi. 48:120–126. 2019.(In
Chinese). PubMed/NCBI
|
|
19
|
Kyo S, Sakaguchi J, Ohno S, Mizumoto Y,
Maida Y, Hashimoto M, Nakamura M, Takakura M, Nakajima M, Masutomi
K and Inoue M: High twist expression is involved in infiltrative
endometrial cancer and affects patient survival. Hum Pathol.
37:431–438. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ihira K, Dong P, Xiong Y, Watari H, Konno
Y, Hanley SJ, Noguchi M, Hirata N, Suizu F, Yamada T, et al: EZH2
inhibition suppresses endometrial cancer progression via
miR-361/Twist axis. Oncotarget. 8:13509–13520. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu HM, Huang HY, Schally AV, Chao A, Chou
HH, Leung PC and Wang HS: Growth hormone-releasing hormone
antagonist inhibits the invasiveness of human endometrial cancer
cells by down-regulating twist and N-cadherin expression.
Oncotarget. 8:4410–4421. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sobel G, Németh J, Kiss A, Lotz G, Szabó
I, Udvarhelyi N, Schaff Z and Páska C: Claudin 1 differentiates
endometrioid and serous papillary endometrial adenocarcinoma.
Gynecol Oncol. 103:591–598. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dhawan P, Singh AB, Deane NG, No Y, Shiou
SR, Schmidt C, Neff J, Washington MK and Beauchamp RD: Claudin-1
regulates cellular transformation and metastatic behavior in colon
cancer. J Clin Invest. 115:1765–1776. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bhat AA, Syed N, Therachiyil L, Nisar S,
Hashem S, Macha MA, Yadav SK, Krishnankutty R, Muralitharan S,
Al-Naemi H, et al: Claudin-1, a double-edged sword in cancer. Int J
Mol Sci. 21:5692020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hol JA, Jongmans MCJ, Littooij AS, de
Krijger RR, Kuiper RP, van Harssel JJT, Mensenkamp A, Simons M,
Tytgat GAM, van den Heuvel-Eibrink MM and van Grotel M: Renal cell
carcinoma in young FH mutation carriers: Case series and review of
the literature. Fam Cancer. 19:55–63. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Castro-Vega LJ, Buffet A, De Cubas AA,
Cascón A, Menara M, Khalifa E, Amar L, Azriel S, Bourdeau I, Chabre
O, et al: Germline mutations in FH confer predisposition to
malignant pheochromocytomas and paragangliomas. Hum Mol Genet.
23:2440–2446. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hvinden IC, Cadoux-Hudson T, Schofield CJ
and McCullagh JSO: Metabolic adaptations in cancers expressing
isocitrate dehydrogenase mutations. Cell Rep Med. 2:10046922021.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Isaacs JS, Jung YJ, Mole DR, Lee S,
Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J, et
al: HIF overexpression correlates with biallelic loss of fumarate
hydratase in renal cancer: Novel role of fumarate in regulation of
HIF stability. Cancer Cell. 8:143–153. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pollard PJ, Brière JJ, Alam NA, Barwell J,
Barclay E, Wortham NC, Hunt T, Mitchell M, Olpin S, Moat SJ, et al:
Accumulation of Krebs cycle intermediates and over-expression of
HIF1alpha in tumours which result from germline FH and SDH
mutations. Hum Mol Genet. 14:2231–2239. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lindner AK, Tulchiner G, Seeber A, Siska
PJ, Thurnher M and Pichler R: Targeting strategies in the treatment
of fumarate hydratase deficient renal cell carcinoma. Front Oncol.
12:9060142022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Peng XH, Karna P, Cao Z, Jiang B-H, Zhou M
and Yang L: Cross-talk between epidermal growth factor receptor and
hypoxia-inducible factor-1alpha signal pathways increases
resistance to apoptosis by up-regulating survivin gene expression.
J Biol Chem. 281:25903–25914. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bhattacharya D and Scimè A: Metabolic
regulation of epithelial to mesenchymal transition: Implications
for endocrine cancer. Front Endocrinol (Lausanne). 10:7732019.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kruiswijk F, Labuschagne CF and Vousden
KH: p53 in survival, death and metabolic health: A lifeguard with a
licence to kill. Nat Rev Mol Cell Biol. 16:393–405. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Contractor T and Harris CR: p53 negatively
regulates transcription of the pyruvate dehydrogenase kinase Pdk2.
Cancer Res. 72:560–567. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Muller PA and Vousden KH: p53 mutations in
cancer. Nat Cell Biol. 15:2–8. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ding J, Li X, Khan S, Zhang C, Gao F, Sen
S, Wasylishen AR, Zhao Y, Lozano G, Koul D and Alfred Yung WK: EGFR
suppresses p53 function by promoting p53 binding to DNA-PKcs: A
noncanonical regulatory axis between EGFR and wild-type p53 in
glioblastoma. Neuro Oncol. 24:1712–1725. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Canale M, Andrikou K, Priano I, Cravero P,
Pasini L, Urbini M, Delmonte A, Crinò L, Bronte G and Ulivi P: The
role of TP53 mutations in EGFR-mutated non-small-cell lung cancer:
Clinical significance and implications for therapy. Cancers
(Basel). 14:11432022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee J and Kim JH: Kaempferol inhibits
pancreatic cancer cell growth and migration through the blockade of
EGFR-related pathway in vitro. PLoS One. 11:e01552642016.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jiang L, Lan T, Chen Y, Sang J, Li Y, Wu
M, Tao Y, Wang Y, Qian H and Gu L: PKG II inhibits EGF/EGFR-induced
migration of gastric cancer cells. PLoS One. 8:e616742013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Holz C, Niehr F, Boyko M, Hristozova T,
Distel L, Budach V and Tinhofer I:
Epithelial-mesenchymal-transition induced by EGFR activation
interferes with cell migration and response to irradiation and
cetuximab in head and neck cancer cells. Radiother Oncol.
101:158–164. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang L, Li Y, Lan L, Liu R, Wu Y, Qu Q
and Wen K: Tamoxifen has a proliferative effect in endometrial
carcinoma mediated via the GPER/EGFR/ERK/cyclin D1 pathway: A
retrospective study and an in vitro study. Mol Cell Endocrinol.
437:51–61. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen CH, Wang SW, Chen CW, Huang MR, Hung
JS, Huang HC, Lin HH, Chen RJ, Shyu MK and Huang MC: MUC20
overexpression predicts poor prognosis and enhances EGF-induced
malignant phenotypes via activation of the EGFR-STAT3 pathway in
endometrial cancer. Gynecol Oncol. 128:560–567. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Singh M and Jadhav HR: Targeting non-small
cell lung cancer with small-molecule EGFR tyrosine kinase
inhibitors. Drug Discov Today. 23:745–753. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang L, Qi Y, Xing K, Qian S, Zhang P and
Wu X: A novel strategy of EGFR-TKI combined chemotherapy in the
treatment of human lung cancer with EGFR-sensitive mutation. Oncol
Rep. 40:1046–1054. 2018.PubMed/NCBI
|
|
45
|
Wang J, Wang C, Hu X, Yu C, Zhou L, Ding Z
and Zhou M: Gefitinib-mediated apoptosis is enhanced via inhibition
of autophagy by chloroquine diphosphate in cutaneous squamous cell
carcinoma cells. Oncol Lett. 18:368–374. 2019.PubMed/NCBI
|
